Metastatic NSCLC salvage therapy has become a critical focus for clinicians since many patients eventually progress on standard anti-PD-1 treatments. The Phase II RECLAIM trial specifically addressed this challenge by evaluating a combination of subablative radiotherapy (RT) and dual checkpoint inhibition. This study focused on patients with low or negative PD-L1 expression, a group that typically faces limited options after initial immunotherapy failure. Furthermore, the trial sought to determine if local radiotherapy could synergize with systemic agents to overcome established resistance mechanisms.

The Synergy of Radiotherapy and Immunotherapy

The trial utilized a unique regimen involving nivolumab and ipilimumab alongside targeted radiotherapy. Consequently, this approach aimed to induce an 'abscopal effect,' where local radiation triggers a systemic immune response. Researchers enrolled 30 evaluable patients who had previously failed anti-PD-1 therapy. Notably, the study focused on those with PD-L1 levels between 1-49% or less than 1%. Therefore, the integration of radiotherapy acts as a potential primer, making the tumor microenvironment more susceptible to dual CTLA-4 and PD-1 blockade.

Clinical Benefits of Metastatic NSCLC Salvage Therapy

The results from the RECLAIM trial suggest that this combination is both safe and potentially effective. Specifically, the triplet therapy provided a manageable safety profile while offering a glimmer of hope for disease control in a difficult-to-treat population. In addition, the findings indicate that local treatment might actually enhance the efficacy of subsequent systemic immunotherapy. Ultimately, these insights provide a framework for future larger-scale trials aimed at formalizing rescue strategies for advanced lung cancer.

Frequently Asked Questions

What was the primary goal of the RECLAIM trial?

The RECLAIM trial was a Phase II study designed to evaluate the safety and efficacy of combining ipilimumab, nivolumab, and subablative radiotherapy in patients with metastatic NSCLC who progressed on prior anti-PD-1 therapy.

Why was radiotherapy included in the regimen?

Radiotherapy was used to potentially prime the immune system. This local treatment can release tumor antigens, thereby enhancing the systemic effectiveness of dual immunotherapy in patients with low PD-L1 expression.

Which patients are most eligible for this salvage approach?

Patients with metastatic NSCLC who have low (1-49%) or negative PD-L1 expression and have already failed a primary anti-PD-1 treatment may benefit from this combined modality approach.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional relationship. Refer to the latest local and national guidelines for clinical practice.

References

Ulas EB et al. Rescue by radiotherapy and anti-CTLA4/PD-1 after failure of anti-PD-1 therapy in patients with metastatic NSCLC: the phase II RECLAIM trial. J Immunother Cancer. 2026 Jun 22. doi: undefined. PMID: 42331381.

Hellmann MD et al. Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2018;378(22):2093-2104.

Theelen WSME et al. Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: The PEMBRO-RT Randomized Clinical Trial. JAMA Oncol. 2019;5(9):1276-1282.